Key facts
- GreenJay Therapeutics’s last known valuation is $20.0M (Jun 2023).
- It has raised $2.0M across 1 recorded rounds; the latest was Seed Round ($1.0M) in Jan 2023.
- Notable investors include Central Texas Angel Network.
- GreenJay Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Apr 2024 ( sold).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for GreenJay Therapeutics
Funding rounds
1 roundsAbout GreenJay Therapeutics
Developer of drug formulations designed for hematological diseases. The company's platform utilizes reformulation to enhance drug solubility, potentially leading to improved clinical outcomes for patients with blood cancers and other related conditions, enabling patients to improve tolerability and compliance, while also increasing physician acceptance.
- Sector
- Healthcare
- HQ
- Conroe, TX, United States
- Founded
- 2022
- Website
- greenjaytherapeutics.com/
- Ownership
- Privately Held (backing)
GreenJay Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GreenJay Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GreenJay Therapeutics in its N-PORT filings yet. We sweep new filings monthly.